大数跨境

马黛茶的身体答卷:一杯茶里,哪些益处有证据《血糖篇》论文分享

马黛茶的身体答卷:一杯茶里,哪些益处有证据《血糖篇》论文分享 马黛茶管理咨询
2026-11-15
0
导读:13项随机对照试验,拆解马黛茶对血糖、血脂与体重的作用;附英文原文、中文翻译与论文出处。
*论文分享, 不构成购买建议,马黛茶是食品并非药品,不能代替药物治疗。

YERBA MATE  ·  深度阅读
马黛茶的身体答卷
一杯茶里,哪些益处有证据,哪些还只是想象
13项随机对照试验  ·  系统综述与Meta分析  ·  约12分钟
马黛茶
马黛茶,南美日常里的一种植物饮品。
一篇论文,不能替一杯茶背书;但它能帮我们分清:哪些益处有证据,哪些只是想象。

在阿根廷的傍晚,公园长椅上常能看到这样一幕:一只葫芦杯在几个人手里传递,金属吸管斜插在杯中,杯底是深绿色的碎叶。热水冲下去,草木与焙火的气息一起升起来。这就是马黛茶,南美人叫它 mate。

它被称作“南美仙草”,也被包装成“燃脂茶”“控糖茶”。可当我们把营销语言拿掉,科学证据到底说了什么?

2025年10月,Frontiers in Endocrinology 发表了一项系统综述与Meta分析。研究团队从1451条文献记录中筛出13项随机对照试验,把马黛茶与安慰剂、水或常规饮食干预放在一起比较。结论并不“炸裂”,却值得认真对待:马黛茶可能有助于血糖控制

这不是一篇“种草文”。我们想做的,是把这篇论文拆开:先看它问了什么、怎么做;再读英文原文的核心段落;然后逐段翻译;最后给出论文出处与完整原文入口。

阅读提示|英文原文为节选,参考文献编号已省略,删节处以〔…〕标示。中文为编者翻译。本文为健康科普,不构成医疗建议。
01   THE PAPER AT A GLANCE / 论文速览
它到底研究了什么?

研究团队来自四川大学华西医院老年医学科、国家老年疾病临床医学研究中心,以及英国拉夫堡大学运动、运动科学与健康学院。论文于2025年10月30日发表于 Frontiers in Endocrinology,属于系统综述与Meta分析:把多项随机对照试验的数据合并,估计马黛茶对代谢指标的平均影响。

他们只纳入随机对照试验(RCT),检索 MEDLINE、EMBASE 和 Cochrane 对照试验中心注册库,时间截至2025年1月15日,不限语言。最终13项研究入选:9项平行设计,4项交叉设计;受试者年龄28~57岁;研究地点包括巴西、韩国、意大利、德国、挪威和阿根廷;人群涵盖健康人、超重或肥胖者、血脂异常者、糖尿病前期患者和HIV感染者。

干预方式并不统一:有的是马黛茶茶饮,每天20克或100克;有的是胶囊或片剂,每天0.5~5克;干预时间从5天到90天不等。这一点很重要——“喝一杯马黛茶”和“吞一颗标准化提取物胶囊”,并不是同一个暴露。

研究问题
马黛茶对血脂、血糖和体重/腰围有何影响?
研究类型
系统综述与Meta分析,仅纳入随机对照试验
数据来源
MEDLINE、EMBASE、Cochrane CENTRAL,截至2025年1月15日
纳入研究
13项RCT:9项平行、4项交叉;受试者年龄28~57岁
干预形式
茶饮(20克或100克/天)或胶囊/片剂(0.5~5克/天)
干预时长
5天~90天
主要结论
可能改善糖尿病前期人群的餐后血糖、HbA1c、HOMA指数;对血脂、空腹血糖/胰岛素、腰围、BMI无显著影响
证据局限
血糖结局仅2项试验、同一团队;证据确定性低;研究间异质性大
图1|论文的“证据地图”:血糖指标出现改善信号,血脂与体重指标未达显著。数据依据论文表3、图3–4重绘。
可能有益
血糖控制
糖尿病前期人群的餐后血糖、HbA1c、HOMA指数出现下降信号。
不能替代
药物与治疗
证据有限,不能用于治疗或预防糖尿病,也不能替代降糖药。
但要注意|血糖结局只来自2项试验,且由同一团队完成;论文给餐后血糖和HbA1c的证据确定性评级为“低”。这意味着:方向值得关注,结论仍需验证。
02   THE PAPER / SELECTED SECTIONS
英文原文 · 核心章节

以下为论文核心章节的英文节选。为便于阅读,参考文献编号已省略,删节处以〔…〕标示;完整原文请见文末出处。建议先读英文,再对照下一节的中文翻译。

01   ENGLISH / ABSTRACT
Abstract

Purpose. Yerba Maté, a traditional South American herbal infusion abundant in bioactive compounds, has been suggested to offer health benefits including lipid regulation and weight management. However, existing evidence remains inconclusive. This systematic review and meta-analysis seeks to conduct a comprehensive evaluation of the effects of Yerba Maté consumption on metabolic health outcomes using data from randomized controlled trials (RCTs).

Methods. In accordance with the PRISMA guidelines, a comprehensive systematic review and meta-analysis of RCTs was conducted, encompassing studies published up to January 2025. Studies were systematically retrieved from MEDLINE, EMBASE and The Cochrane Central Register of Controlled Trials without any language restrictions. The review included RCTs that evaluated the impact of Yerba Maté on metabolic health indicators. Meta-analyses were performed using Review Manager (RevMan 5.4) when two or more studies from the same comparator provided sufficient data. Quality assessment were assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2) tool. The overall quality of evidence was evaluated using the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) method.

Results. A total of 1294 studies were initially identified, of which 13 RCTs met the inclusion criteria. The study population includes dyslipidemic volunteers, overweight and obese and non-dyslipidemic, normal-weight volunteers. The results with pre-diabetes patients suggest significant decreases in postprandial glucose (MD -12.76, 95% CI -16.78, -8.74; N = 2), HbA1c (MD -0.37, 95% CI -0.56, -0.18; N = 2), and the homeostatic model assessment index (HOMA index) (MD -0.24, 95% CI -0.37, -0.11; N = 2), though further research is needed to confirm these findings. No significant effects were found on triglycerides, total cholesterol, HDL-C, LDL-C, fasting glucose, fasting insulin, waist circumference, or BMI.

Conclusion. Yerba Maté consumption may demonstrate favorable effects on glycemic control, though its impact on lipid profiles and weight management appears to be limited.

NOTE  N=2 指纳入该指标合并分析的试验数量,不是受试者人数。MD=均数差;CI=置信区间。
02   ENGLISH / INTRODUCTION
Introduction

Ilex paraguariensis, or Yerba Maté, is a South American plant mainly grown in northern Argentina, Paraguay, Uruguay, and the south of Brazil. The history of this plant is long, and its cultural roots are deep in South America, where it is extensively used in social activities and day-to-day consumption. Because of its unique bitter taste and pleasant aroma, it’s a beverage popular not only in South America but also increasingly globally. This beverage constitutes a sophisticated matrix comprising bioactive constituents, including chlorogenic acid, polyphenolic compounds, saponins, and methylxanthine derivatives such as caffeine, theobromine, and theophylline.

Existing studies also indicate that consumption of Yerba Maté may offer potential health benefits, but the results of these studies are inconsistent. As such, the aim of this systematic review is to provide a comprehensive review of the effects of Yerba Maté about health outcomes, such as lipid profiles, blood glucose levels, weight management and potentially harmful effects of consumption, by searching for evidence published in randomized controlled trials (RCTs).

03   ENGLISH / RESULTS
Results

Study selection. A total of 1451 citations were identified through the initial database search. After eliminating duplicates and screening titles, 1294 citations were considered potentially relevant. […] Ultimately, 13 RCTs fulfilled the inclusion criteria for this systematic review and meta-analysis.

Study characteristics. The 13 studies enrolled participants with ages ranging from 28 to 57 years. Among these studies, 9 were parallel RCTs and 4 were crossover RCTs. […] Interventions were delivered as Yerba Maté capsules or as Yerba Maté tea. Daily capsule doses ranged from 0.5 g, 1.0 g, 2.25 g, 3.0 g to 5 g; tea doses were 20 g or 100 g. Treatment durations spanned 5 days, 15 days, 4 weeks, 6 weeks, 60 days, 3 months, 12 weeks and 90 days.

Effects on blood glucose metabolism. Seven RCTs were included to evaluate the effects of Yerba Maté on glycemic status, with follow-up durations ranging from 5 days to 3 months. […] Meta-analysis revealed a significant reduction in postprandial glucose levels (MD -12.76, 95% CI -16.78 to -8.74, I² = 91%, p=0.001, N = 2), HbA1c levels (MD -0.37, 95% CI -0.56 to -0.18, I² = 64%, p=0.1; N = 2) and the HOMA index (MD -0.24, 95% CI -0.37 to -0.11, I² = 0%, p=0.82; N = 2). No significant differences were observed in fasting glucose levels or fasting insulin concentrations between the Yerba Maté group and the control group.

Impact on lipid levels. A total of 11 RCTs were included to assess the impact of Yerba Maté on lipid levels, with follow-up durations ranging from 15 to 90 days. Comparative analysis of Yerba Maté versus control groups demonstrated non-significant differences in total cholesterol, triglycerides, HDL-C or LDL-C.

Influence on weight management. Eight RCTs were included to assess the effects of Yerba Maté on waist circumference and BMI, with follow-up durations ranging from 4 weeks to 3 months. Comparative meta-analysis showed no significant differences in waist circumference or BMI between Yerba Maté and control groups.

NOTE  I² 描述研究间异质性;p 值用于判断异质性或合并效应是否具有统计学意义。数值大小不等于临床效果大小。
04   ENGLISH / DISCUSSION
Discussion

Principal findings. Our systematic review and meta-analysis demonstrate that Yerba Maté consumption may improve glycemic outcomes, including decreased postprandial glucose levels, HbA1c levels, and the HOMA index. However, no significant effects were observed on lipid profiles (triglycerides, total cholesterol, HDL-C, LDL-C), waist circumference, or BMI. These findings suggest that Yerba Maté may exert glycemic control benefits independent of lipid metabolism modulation.

It is important to highlight that the two studies indicating Yerba Maté’s beneficial effects on blood glucose were conducted by the same research team, which may introduce reporting bias and warrants cautious interpretation. […] However, it should be noted that the two studies were conducted by the same research team and used a standardized formulation produced by the same company. This might lead to reporting bias. Therefore, their positive results should be interpreted with caution.

05   ENGLISH / CONCLUSION
Conclusion

In summary, our systematic review and meta-analysis suggest that Yerba Maté consumption may significantly reduce postprandial glucose, HbA1c, and HOMA index. However, it did not show significant impacts on total cholesterol, triglycerides, HDL-C, LDL-C, fasting glucose, fasting insulin, waist circumference, or BMI, and further research is needed to confirm these preliminary findings. […] The overall findings suggest that Yerba Maté may exert glycemic control benefits independent of lipid metabolism modulation. Future research should address the identified limitations and knowledge gaps through large-scale, rigorously designed RCTs and longitudinal cohort studies.

03   TRANSLATION / 中文对照
中文翻译

以下中文为编者对照原文的翻译。专业术语首次出现时保留英文缩写;翻译力求准确,但不替代原文。

01   中文 / 摘要
摘要

目的: 马黛茶是南美洲一种传统的草本饮品,富含生物活性成分。既往研究提示,它可能具有调节血脂、管理体重等健康益处,但现有证据仍不明确。本系统综述与Meta分析旨在基于随机对照试验(RCT)的数据,全面评估饮用马黛茶对代谢健康结局的影响。

方法: 遵循PRISMA指南,开展了一项纳入截至2025年1月已发表研究的系统综述与Meta分析。研究系统检索了MEDLINE、EMBASE和Cochrane对照试验中心注册库,不限语言。纳入评估马黛茶对代谢健康指标影响的RCT。当同一对照组的至少两项研究提供足够数据时,使用Review Manager(RevMan 5.4)进行Meta分析。采用修订版Cochrane随机试验偏倚风险工具(RoB 2)评估质量,并采用GRADE(推荐分级的评估、制定与评价)方法评价证据总体质量。

结果: 初步共识别1294项研究,其中13项RCT符合纳入标准。研究人群包括血脂异常志愿者、超重和肥胖者,以及非血脂异常、体重正常的志愿者。在糖尿病前期患者中,结果提示餐后血糖(MD -12.76,95% CI -16.78~-8.74;N=2)、HbA1c(MD -0.37,95% CI -0.56~-0.18;N=2)和稳态模型评估指数(HOMA指数)(MD -0.24,95% CI -0.37~-0.11;N=2)显著下降,但仍需进一步研究确认。甘油三酯、总胆固醇、HDL-C、LDL-C、空腹血糖、空腹胰岛素、腰围和BMI均未见显著影响。

结论: 饮用马黛茶可能对血糖控制产生有利影响

译注  N=2 指纳入该指标合并分析的试验数量,不是受试者人数。MD=均数差;CI=置信区间。
02   中文 / 引言
引言

巴拉圭冬青(Ilex paraguariensis),即马黛茶,是一种主要生长在阿根廷北部、巴拉圭、乌拉圭和巴西南部的南美植物。它的历史悠久,文化根基深植于南美,广泛用于社交活动和日常饮用。因其独特的苦味和宜人的香气,马黛茶不仅在南美流行,也在全球范围内日益受到欢迎。这种饮品是一个复杂的基质,含有绿原酸、多酚类化合物、皂苷,以及咖啡因、可可碱和茶碱等甲基黄嘌呤衍生物。

现有研究还提示,饮用马黛茶可能带来潜在健康益处,但研究结果并不一致。因此,本系统综述旨在通过检索已发表的随机对照试验证据,全面评估马黛茶对血脂谱、血糖水平、体重管理以及潜在有害作用等健康结局的影响。

03   中文 / 结果
结果

研究筛选: 初步数据库检索共识别1451条引文。去除重复并筛选标题后,1294条被认为可能相关。〔……〕最终,13项RCT符合本系统综述与Meta分析的纳入标准。

研究特征: 13项研究纳入的受试者年龄为28~57岁。其中9项为平行RCT,4项为交叉RCT。〔……〕干预形式为马黛茶胶囊或马黛茶茶饮。胶囊日剂量包括0.5克、1.0克、2.25克、3.0克至5克;茶饮日剂量为20克或100克。干预时长包括5天、15天、4周、6周、60天、3个月、12周和90天。

对血糖代谢的影响: 共纳入7项RCT评估马黛茶对血糖状态的影响,随访时间为5天至3个月。〔……〕Meta分析显示,餐后血糖(MD -12.76,95% CI -16.78~-8.74,I²=91%,p=0.001,N=2)、HbA1c(MD -0.37,95% CI -0.56~-0.18,I²=64%,p=0.1;N=2)和HOMA指数(MD -0.24,95% CI -0.37~-0.11,I²=0%,p=0.82;N=2)显著下降。马黛茶组与对照组在空腹血糖和空腹胰岛素浓度上未见显著差异。

对血脂的影响: 共纳入11项RCT评估马黛茶对血脂的影响,随访时间为15~90天。与对照组相比,马黛茶在总胆固醇、甘油三酯、HDL-C和LDL-C上均未显示显著差异。

对体重管理的影响: 共纳入8项RCT评估马黛茶对腰围和BMI的影响,随访时间为4周至3个月。Meta分析显示,马黛茶组与对照组在腰围和BMI上均无显著差异。

译注  I² 描述研究间异质性;p 值用于判断异质性或合并效应是否具有统计学意义。数值大小不等于临床效果大小。
04   中文 / 讨论
讨论

主要发现: 本系统综述与Meta分析表明,饮用马黛茶可能改善血糖结局,包括降低餐后血糖、HbA1c和HOMA指数。然而,在血脂谱(甘油三酯、总胆固醇、HDL-C、LDL-C)、腰围或BMI方面,未观察到显著影响。这些发现提示,马黛茶可能在不依赖脂质代谢调节的情况下,产生血糖控制方面的益处。

需要强调的是,提示马黛茶对血糖有益的这两项研究由同一个研究团队完成,可能引入报告偏倚,因此应谨慎解读。〔……〕但应注意,两项研究由同一团队完成,使用的是同一家公司生产的标准化制剂,这可能带来报告偏倚。因此,对其阳性结果应谨慎解读。

05   中文 / 结论
结论

总之,本系统综述与Meta分析提示,饮用马黛茶可能显著降低餐后血糖、HbA1c和HOMA指数。其他未显示出显著影响,仍需进一步研究确认这些初步发现。〔……〕总体结果提示,马黛茶可能在不依赖脂质代谢调节的情况下产生血糖控制益处。未来研究应通过大规模、严格设计的RCT和纵向队列研究,解决已发现的局限和知识空白。

04   REFERENCE / 论文出处
原文、作者与引用信息
CITATION  /  引用信息

Li D, Yue L, Peng X, Chen L, Lin T, Huang L, Liu Y, Yue J, Huang X. Yerba Maté and its impact on glycemic control and metabolic health: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:1641592. doi:10.3389/fendo.2025.1641592

英文标题:Yerba Maté and its impact on glycemic control and metabolic health: a systematic review and meta-analysis

中文译名:马黛茶对血糖控制与代谢健康的影响:一项系统综述与Meta分析

作者:Daiping Li, Liantian Yue, Xuchao Peng, Ling Chen, Taiping Lin, Li Huang, Yadong Liu, Jirong Yue, Xiaoli Huang

机构:四川大学华西医院老年医学科、国家老年疾病临床医学研究中心;英国拉夫堡大学运动、运动科学与健康学院

期刊:Frontiers in Endocrinology (Lausanne)

发表:2025; 16:1641592(2025年10月30日)

DOI:10.3389/fendo.2025.1641592

PMID / PMCID:41244043 / PMC12611702

注册号:PROSPERO CRD42023369270

许可:CC BY 4.0

DOI 原文:https://doi.org/10.3389/fendo.2025.1641592
PMC 全文:https://pmc.ncbi.nlm.nih.gov/articles/PMC12611702/

本文英文部分为原文节选,删节处以〔…〕标示;中文为编者翻译,供学习交流,不代表原作者。原文以CC BY 4.0许可发布,引用请注明出处。本文插图由编者绘制,数据图依据论文表3、图3–4重绘,不是论文原图。

本文为健康科普,不构成医疗建议、诊断或治疗依据。马黛茶不能替代药物、均衡饮食和规律运动。

A BOTANICAL READING  ·  植物、证据与日常  |  健康科普 · 不构成医疗建议

【声明】内容源于网络
0
0
马黛茶管理咨询
帕拉纳马黛茶,唯一具有阿根廷官方授权总代理商,专业咨询及销售阿根廷国宝马黛茶,权威的资讯及服务,我们以正能量传播健康及分享事业机会,欢迎您的加盟。
内容 194
粉丝 0
马黛茶管理咨询 帕拉纳马黛茶,唯一具有阿根廷官方授权总代理商,专业咨询及销售阿根廷国宝马黛茶,权威的资讯及服务,我们以正能量传播健康及分享事业机会,欢迎您的加盟。
总阅读2.9k
粉丝0
内容194